Articles By RheumNow
DMARD Switching in Psoriatic Arthritis
By RheumNow
Switching biologic disease-modifying anti-rheumatic drug (bDMARD) therapy after failure of a first bDMARD for the treatment of psoriatic arthritis (PsA) can be effective, according to a review of the literature and PsA consensus treatment recommendations.
Read Article
Drugs Contribute to Infectious Risks in Lupus
By RheumNow
Multiple patient- and disease-related factors -- including medication use -- were associated with the development of severe infections among patients with systemic lupus erythematosus, a Spanish study found.
Read ArticleThe High Cost of Psoriatic Arthritis
By RheumNow
New research confirms that patients with psoriatic arthritis (PsA) face significant healthcare and socioeconomic hurdles.
Read Article
Lupus in Kids: Damage Starts Early
By RheumNow
A new study sheds important light on the long-term outcomes of children diagnosed with systemic lupus erythematosus (SLE).
Read Article
Increased Cardiovascular Risk with Gout
By RheumNow
Most patients who present with gout to rheumatology clinics are at very high risk of cardiovascular (CV) disease, Spanish researchers found.
Read Article
Osteoporosis 2016 Year in Review - No new drug approvals, and a crisis in care
By RheumNow
No new osteoporosis drugs hit the market this year, but two are progressing through the development pipeline and are showing promise.
Read Article
Nonsignificant CV Risk with Actemra vs Enbrel
By RheumNow
WASHINGTON -- Rheumatoid arthritis is a recognized risk factor for heart attacks and stroke, but a study comparing two leading biologics found only a non-significant increase in relative risk for patients treated with toclizimab (Actemra) vs etanercept (Enbrel), researchers reported here.
Read Article
Higher Lupus Disease Activity in First Year Postpartum
By RheumNow
Most women with systemic lupus erythematosus (SLE) have no or little disease activity during pregnancy, but experience greater disease activity or overt flares during the first year postpartum, a Norwegian study has found.
Read Article
Michelle Petri Reviews New Therapies for Lupus
By RheumNow
In this video, Michelle Petri, MD, director of the Hopkins Lupus Center at Johns Hopkins University, discusses recent successes and challenges in the treatment of systemic lupus erythematosus, with clinical trials results ranging from "wildly positive" to "completely negative."
Read Article